{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:39:38Z","timestamp":1791214778376,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2003,2]]},"DOI":"10.1007\/bf02983215","type":"journal-article","created":{"date-parts":[[2008,11,5]],"date-time":"2008-11-05T12:17:19Z","timestamp":1225887439000},"page":"164-170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Deoxycoformycin-Containing Combination Chemotherapy for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study (JCOG9109)"],"prefix":"10.1007","volume":"77","author":[{"name":"Members of the Lymphoma Study Group (LSG) of the Japan Clinical Oncology Group (JCOG)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensci","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Shimoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Kozuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naokuni","family":"Uikc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Tomonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Takatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Tara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Mikuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomitsu","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,2,1]]},"reference":[{"key":"BF02983215_CR1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","volume":"50","author":"T Uchiyama","year":"1977","unstructured":"Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and h\u00e9matologie features of 16 cases.Blood. 1977;50:481\u2013492.","journal-title":"Blood."},{"key":"BF02983215_CR2","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","volume":"79","author":"M Yoshida","year":"1982","unstructured":"Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T cell leukemia and its implication in the disease.Proc Natl Acad Sei 11 S A. 1982;79:2031\u20132035.","journal-title":"Proc Natl Acad Sei 11 S A."},{"key":"BF02983215_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"M. Shimoyama","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical sub-types of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984\u201387).Br J Haematol. 1991;79:428\u2013437.","journal-title":"Br J Haematol."},{"key":"BF02983215_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1046\/j.1365-2141.1998.00582.x","volume":"100","author":"R Pawson","year":"1998","unstructured":"Pawson R, Mufti GJ, Pagliuca A. Management of adult T-cell lcukacmia\/lyraphoraa.Br J Haematol. 1998;100:453\u2013458.","journal-title":"Br J Haematol."},{"key":"BF02983215_CR5","first-page":"2748","volume-title":"Clinical Oncology","author":"K. Tobinai","year":"2000","unstructured":"Tobinai K. Adult T-cell lcukcmia-lymphoma. In: Abeloff MD, Arraitagc JO, Lichter AS, Nicdcrhubcr JE. eds.Clinical Oncology. 2nd ed. New York, NY: Churchill Livingstone; 2000:2748\u20132768.","edition":"2nd ed."},{"key":"BF02983215_CR6","first-page":"221","volume-title":"Adult T-cell Leukemia","author":"M. Shimoyama","year":"1994","unstructured":"Shimoyama M. Chemotherapy of ATL. In: Takatsuki K, ed.Adult T-cell Leukemia. Oxford, UK: Oxford University Press; 1994:221\u2013237."},{"key":"BF02983215_CR7","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1182\/blood.V76.10.2065.2065","volume":"76","author":"Y Kuwazuru","year":"1990","unstructured":"Kuwazuru Y, Hanada S, Furukawa T, et al. Expression of P-glycoprotein in adult T-cell leukemia cells.Blood. 1990;76:2065\u20132071.","journal-title":"Blood."},{"key":"BF02983215_CR8","first-page":"599","volume":"82","author":"K Tkeda","year":"1999","unstructured":"Tkeda K, Oka M, Yamada Y, et al. Adult T-celI leukemia cells overexpress the multidrug-resistance-protein (MRP) and lung-resistance-protein (LRP) genes.M J Cancer. 1999;82:599\u2013604.","journal-title":"M J Cancer."},{"key":"BF02983215_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1053\/beha.1999.0070","volume":"13","author":"K Tsukasaki","year":"2000","unstructured":"Tsukasaki K, Koeffler P, Tomonaga M. Human T-lymphotropic virus type 1 infection.Baillieres Best Pract Res Clin Haematol. 2000;13:231\u2013243.","journal-title":"Baillieres Best Pract Res Clin Haematol."},{"key":"BF02983215_CR10","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1200\/JCO.1995.13.4.974","volume":"13","author":"M Grever","year":"1995","unstructured":"Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study.J Clin Oncol. 1995;13:974\u2013982.","journal-title":"J Clin Oncol."},{"key":"BF02983215_CR11","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1182\/blood.V96.1.71","volume":"96","author":"IW Flinn","year":"2000","unstructured":"Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin.Blood. 2000;96:2981\u20132986.","journal-title":"Blood."},{"key":"BF02983215_CR12","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","volume":"12","author":"J Mercieca","year":"1994","unstructured":"Mercieca J, Matutes E, Dearden C, MacLenn an K, Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype.J. Clin Oncol. 1994;12:2588\u20132593.","journal-title":"J. Clin Oncol."},{"key":"BF02983215_CR13","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1023\/A:1008377724139","volume":"10","author":"AD Ho","year":"1999","unstructured":"Ho AD, Suciu S, Stryckmans P, et al. Pentostatin in T-cell malignancies: a phase II trial of the EORTC Leukemia Cooperative Group.Ann Oncol. 1999;10:1493\u20131498.","journal-title":"Ann Oncol."},{"key":"BF02983215_CR14","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1200\/JCO.1999.17.10.3117","volume":"17","author":"R Kurzrock","year":"1999","unstructured":"Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations.J. Clin Oncol. 1999;17:3117\u2013321.","journal-title":"J. Clin Oncol."},{"key":"BF02983215_CR15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V57.3.406.406","volume":"57","author":"MR Grever","year":"1981","unstructured":"Grever MR, Siaw ME, Jacob WE, et al. The biochemical and clinical consequences of 2\u2019-deoxycoformycin in refractory lymphoproliferative malignancy.Blood. 1981;57:406\u2013417.","journal-title":"Blood."},{"key":"BF02983215_CR16","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/1097-0142(19870815)60:4<750::AID-CNCR2820600407>3.0.CO;2-1","volume":"60","author":"D K\u00f6rte de","year":"1987","unstructured":"de K\u00f6rte D, Haverkort WA, van Leeuwen EF, Roos D, van Gennip AH. Biochemical consequences of 2\u2019-deoxycoformycin treatment in a patient with T-cell lymphoma: some unusual findings.Cancer. 1987;60:750\u2013755.","journal-title":"Cancer."},{"key":"BF02983215_CR17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood.V58.1.91.91","volume":"58","author":"PP Major","year":"1981","unstructured":"Major PP, Agarwal RP, Kufe DW. Clinical pharmacology of deoxycoformycin.Blood. 1981;58:91\u201396.","journal-title":"Blood."},{"key":"BF02983215_CR18","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1365-2141.1984.tb06119.x","volume":"58","author":"S Daenen","year":"1984","unstructured":"Daenen S, Rojer RA, Smit JW, Halie MR, Nieweg HO. Successful chemotherapy with deoxycoformycin in adult T-cell lymphomaleukaemia.Br.I Haematol 1984;58:723\u2013727.","journal-title":"Br.I Haematol"},{"key":"BF02983215_CR19","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/0145-2126(86)90251-1","volume":"10","author":"K Yamaguchi","year":"1986","unstructured":"Yamaguchi K, Yul LS, Oda T, et al. Clinical consequences of 2\u2019-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia.Leuk Res. 1986;10:989\u2013993.","journal-title":"Leuk Res."},{"key":"BF02983215_CR20","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1002\/1097-0142(19871201)60:11<2605::AID-CNCR2820601104>3.0.CO;2-T","volume":"60","author":"W Lofters","year":"1987","unstructured":"Lofters W, Campbell M, Gibbs WN, Cheson BD. 2\u2019-Deoxycoformycin therapy in adult T-cell leukemia\/lymphoma.Cancer. 1987;60:2605\u20132608.","journal-title":"Cancer."},{"key":"BF02983215_CR21","first-page":"164","volume":"22","author":"K Tobinai","year":"1992","unstructured":"Tobinai K, Shimoyama M, Inoue S, et al. Phase I study of YK-176 (2\u2019-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma: the DCF Study Group.Jpn J Clin Oncol. 1992;22:164\u2013171.","journal-title":"Jpn J Clin Oncol."},{"key":"BF02983215_CR22","first-page":"2375","volume":"43","author":"K Kodama","year":"1979","unstructured":"Kodama K, Kusakabe H, Machida H, et al. Isolation of 2\u2019-deoxycoformycin and cordyceptin from wheat bran culture ofAspergillus nidulans Y 176-2.Agric Biol Chem. 1979;43:2375\u20132377.","journal-title":"Agric Biol Chem."},{"key":"BF02983215_CR23","first-page":"217","volume":"12","author":"J Gryn","year":"1993","unstructured":"Gryn J, Gordon R, Bapat A, Goldman N, Goldberg J. Pentostatin increases the acute toxicity of high dose cyclophosphamide.Bone Marrow Transplant. 1993;12:217\u2013220.","journal-title":"Bone Marrow Transplant."},{"key":"BF02983215_CR24","first-page":"378","volume":"13","author":"K Tobinai","year":"1994","unstructured":"Tobinai K, Shimoyama M, Minato K, et al. Japan Clinical Oncology Group phase II trial of second-generation \u201cLSG4 protocol\u201d in aggressive T- and B-lymphoma: a new predictive model forT-and B~lymphoma [abstract].Proc Am Soc Clin Oncol. 1994;13:378.","journal-title":"Proc Am Soc Clin Oncol."},{"key":"BF02983215_CR25","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1200\/JCO.1993.11.8.1573","volume":"11","author":"WH Wilson","year":"1993","unstructured":"Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin\u2019s lymphoma.J. Clin Oncol. 1993;11:1573\u20131582.","journal-title":"J. Clin Oncol."},{"key":"BF02983215_CR26","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","volume":"12","author":"WS Velasquez","year":"1994","unstructured":"Velasquez WS, McLaughlin P,Tucker S, et al. ESHAP\u2014an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.Clin Oncol. 1994;12:1169\u20131176.","journal-title":"Clin Oncol."},{"key":"BF02983215_CR27","first-page":"392","volume":"28","author":"K Tanaka","year":"1987","unstructured":"Tanaka K, Rgami K, Nakamura E, et al. A case of ATI, presenting a huge intrahepatic tumor, abated with etoposide (NK-171) therapy alone [in Japanese].Rinsho Kelsueki. 1987;28:392\u2013397.","journal-title":"Rinsho Kelsueki."},{"key":"BF02983215_CR28","first-page":"319","volume":"13","author":"A Wakui","year":"1986","unstructured":"Wakui A, YokoyamaM.Takahashi H, et al. A phase I study of VP-16-213 (VP, etoposide) by single and 5-day intravenous administration [in Japanese],Can To Kagaku Ryoho. 1986;13:319\u2013329.","journal-title":"Can To Kagaku Ryoho."},{"key":"BF02983215_CR29","first-page":"2145","volume":"15","author":"K Naito","year":"1988","unstructured":"Naito K, Kobayashi M, Oyama A, et al. Phase II study of carbo-platin in malignant lymphoma [in Japanese].Gan To Kagaku Ryoho. 1988;15:2145\u20132151.","journal-title":"Gan To Kagaku Ryoho."},{"key":"BF02983215_CR30","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RII, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group.Am J Clin Oncol. 1982;5:649\u2013655.","journal-title":"Am J Clin Oncol."},{"key":"BF02983215_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/jjco\/28.3.158","volume":"28","author":"M Shimoyama","year":"1998","unstructured":"Shimoyama M, Fukuda H, Saijo N, Yamaguchi N. Japan Clinical Oncology Group (JCOG).Jpn J Clin Oncol. 1998;28:158\u2013162.","journal-title":"Jpn J Clin Oncol."},{"key":"BF02983215_CR32","volume-title":"WHO Handbook for Reporting Results of Cancer Treatment.","author":"World Health Organization","year":"1979","unstructured":"World Health Organization.WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979. WHO Offset Publication No. 48."},{"key":"BF02983215_CR33","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","volume":"113","author":"Y,Tomonaga M Yamada","year":"2001","unstructured":"Yamada Y,Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303.Br.1 Haematol. 2001;113:375\u2013382.","journal-title":"Br .1 Haematol."},{"key":"BF02983215_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.J am Stat Assoc. 1958;53:157\u2013181.","journal-title":"J am Stat Assoc."},{"key":"BF02983215_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1200\/JCO.1988.6.1.128","volume":"6","author":"M Shimoyama","year":"1988","unstructured":"Shimoyama M, Ota K, Kikuchi M, et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin\u2019s lymphoma treated with VEPA or VEPA-M.J. Clin Oncol. 1988;6:128\u2013141.","journal-title":"J. Clin Oncol."},{"key":"BF02983215_CR36","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1200\/JCO.1988.6.7.1088","volume":"6","author":"M Shimoyama","year":"1988","unstructured":"Shimoyama M, Ota K, Kikuchi M, et al. Major prognostic factors of adult patients with advanced T-cell Iymphoma\/leukemia.J. Clin Oncol. 1988;6:1088\u20131097.","journal-title":"J. Clin Oncol."},{"key":"BF02983215_CR37","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dah Iberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma.N Engl J Med. 1993;328:1002\u20131006.","journal-title":"N Engl J Med."},{"key":"BF02983215_CR38","first-page":"38","volume":"73","author":"WJ Urba","year":"1989","unstructured":"Urba WJ, Baseler MW, Kopp WC, et al. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia.Blood. 1989;73:38\u201346.","journal-title":"Blood."},{"key":"BF02983215_CR39","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V82.6.1701.1701","volume":"82","author":"TA Waldmann","year":"1993","unstructured":"Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia.Blood. 1993;82:1701\u20131712.","journal-title":"Blood."},{"key":"BF02983215_CR40","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063","volume":"86","author":"TA Waldmann","year":"1995","unstructured":"Waldmann TA, White JD, Carrasquillo JA, et al. Radioim-munothcrapy of intcrlcukin-2R a-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac.Blood. 1995;86:4063\u20134075.","journal-title":"Blood."},{"key":"BF02983215_CR41","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1182\/blood.V81.10.2810.2810","volume":"81","author":"JA Sparano","year":"1993","unstructured":"41. Sparano JA, Wiernik PH, Strack M, Leaf A, Becker N, Valentine ES. Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type I-related non-Hodgkin\u2019s lymphoma: a highly active regimen.Blood. 1993;81:2810\u20132815.","journal-title":"Blood."},{"key":"BF02983215_CR42","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/00042560-199606010-00012","volume":"12","author":"H Taguchi","year":"1996","unstructured":"Taguchi H, Kinoshita K, Takatsuki K, et al. An intensive chemotherapy of adult T-cell leukemia\/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support.J Acquir Immune Defic Syndr Him Retroviral. 1996;12:182\u2013186.","journal-title":"J Acquir Immune Defic Syndr Him Retroviral."},{"key":"BF02983215_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/sj.bmt.1702731","volume":"27","author":"A Utsunomiya","year":"2001","unstructured":"Utsunomiya A, Miyazaki Y,Takatsuka Y, et al. Improved outcome of adult T cell leukemia\/lymphoma with allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplant. 2001;27:15\u201320.","journal-title":"Bone Marrow Transplant."},{"key":"BF02983215_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/BF02982725","volume":"76","author":"Y Abe","year":"2002","unstructured":"Abe Y, Yashiki S, Choi I, et al. Eradication of virus-infected T-cells in a case of adult T-cell leukemia\/lymphoma by nonmyeloablative peripheral blood stem cell transplantation with conditioning consisting of low-dose total body irradiation and pentostatin.Int J Hematol. 2002;76:91\u201393.","journal-title":"Int J Hematol."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02983215\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02983215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02983215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02983215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T18:28:09Z","timestamp":1589048889000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02983215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["BF02983215"],"URL":"https:\/\/doi.org\/10.1007\/bf02983215","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}